Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

LESSONS LEARNED: Radiotherapy plus anti–PD‐1 antibody as first‐line therapy is safe and feasible in locally advanced esophageal squamous cell carcinoma (ESCC). Tumor‐infiltrating and peripheral lymphocytes were associated with patient survival. Further studies combining chemoradiotherapy with immuno...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Zhang, Wencheng, Yan, Cihui, Gao, Xuan, Li, Xiaoxia, Cao, Fuliang, Zhao, Gang, Zhao, Jingjing, Er, Puchun, Zhang, Tian, Chen, Xi, Wang, Yuwen, Jiang, Yao, Wang, Quanren, Zhang, Baozhong, Qian, Dong, Wang, Jun, Zhou, Dejun, Ren, Xiubao, Yu, Zhentao, Zhao, Lujun, Yuan, Zhiyong, Wang, Ping, Pang, Qingsong
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265339/
https://ncbi.nlm.nih.gov/pubmed/33893689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13797
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados